by Chronic Obstructive Pulmonary Disease (COPD) refers to a group of lung diseases that block airflow and make breathing difficult. It includes emphysema and chronic bronchitis. Symptoms of COPD include wheezing, chronic cough, shortness of breath during activity and excess sputum production. COPD is often caused due to exposure to cigarette smoke or air pollutants. COPD treatment includes use of pulmonary drugs like bronchodilators and steroids to expand the airways and reduce inflammation and infection. Pulmonary rehabilitation programs are also used to improve patient symptoms and quality of life. Long-acting bronchodilators are becoming the standard treatment for patients with moderate to severe COPD.
The Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is estimated to be valued at US$ 20.86 Mn in 2024 and is expected to exhibit a CAGR of 6.1% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Chronic Obstructive Pulmonary Disease (COPD) Treatment are First Sensor AG, Bosch Sensortec GmbH, Honeywell International Inc., Murata Manufacturing Co. Ltd., ROHM Co. Ltd., Amphenol Corporation, InvenSense Inc. (TDK Corporation), Sensata Technologies Inc., NXP Semiconductors NV (Freescale), Goertek Inc., TE Connectivity Ltd., STMicroelectronics NV, Infineon Technologies AG, Omron Corporation, and Alps Alpine Co. Ltd.
The growing prevalence of COPD due to rising pollution and growing smoking rates is expected to drive the market during the forecast period. As per WHO, COPD is currently the third leading cause of death worldwide.
Key players are expanding their production facilities globally especially in developing countries of Asia Pacific and Latin America to tap the high growth opportunities. This is expected to boost the access to COPD treatment in these regions.
Market Key Trends
One of the key trends observed in the COPD treatment market is the growing adoption of digital health solutions. Companies are developing digital COPD management programs comprising online monitoring tools, telehealth consultations and remote patient monitoring devices. These solutions help in better disease management and reduce healthcare costs by preventing frequent hospital visits. For example, Philips has launched online digital programs to offer disease education, remote monitoring and personal coaching to COPD patients.
Porter’s Analysis
Threat of new entrants: Low economies of scale, high costs of R&D for new drugs make entry difficult.
Bargaining power of buyers: Large buyers like public healthcare systems can negotiate lower prices, increase competition between existing brands.
Bargaining power of suppliers: High dependence on few raw material suppliers increases supplier bargaining power.
Threat of new substitutes: Emergence of therapies targeting alternative pathways may reduce demand for existing drugs.
Competitive rivalry: Intense competition between leading brands drives innovation and price declines.
Geographical regions
North America accounted for the largest share of the COPD treatment market in 2024, with the US being the major revenue generator. Europe was the second largest regional market aided by rising pollution levels and an aging population. Asia Pacific is expected to experience the fastest growth during the forecast period due to developing healthcare infrastructure and growing awareness.
Fastest growing region
The Asia Pacific region is poised to register the fastest growth in the COPD treatment market between 2024 to 2031. This can be attributed to rising air pollution, growing elderly population, increasing healthcare spending and improving access to diagnosis and care. Countries like China and India will drive a major share of the regional market growth supported by their large population sizes and evolving economic conditions.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
